Numira acquires Ricerca' Efficacy Pharmacology operating unit

Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, announced today that it has acquired the Efficacy Pharmacology operating unit of Ricerca Biosciences, LLC., located in Bothell, WA.

The acquisition brings a state-of-the-art, GLP compliant facility, with a highly talented team, and a broad range of laboratory capabilities to Numira.  "The Bothell site has a long- standing, strong reputation in the CRO market and possesses deep scientific expertise in several therapeutic areas that complement Numira's imaging technology," said Michael Beeuwsaert, CEO of Numira.  "By combining our respective strengths, we are well positioned to provide even greater value to both Numira's and Ricerca's clients, and pursue new opportunities for growth." With this transaction, Numira is able to offer clients comprehensive solutions that include in-life models and studies, high-resolution quantitative imaging, histology, and immunohistochemistry services.

Numira will immediately begin integrating the two companies' services, operations, and employees to ensure a smooth transition of clients and projects.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Key reason why some cancers do not respond to immunotherapy identified